Vol 2, No 2 (2011)
Review paper
Published online: 2011-07-15
The role of hematopoietic stem cell transplantation in the treatment of patients with plasma cell myeloma
Hematologia 2011;2(2):131-139.
Abstract
Autologous hematopoietic stem cell transplantation (auto-HSCT) is still standard method in
the frontline therapy of patients with plasma cell myeloma younger than 65 years. Novel
agents, e.i. thalidomide, lenalidomide, bortezomib are incorporated into all phases of therapy,
including: induction, conditioning, consolidation and maintenance. It results in higher preand
posttransplantation complete remission (CR) rates and leads to a longer overall survival.
Allogeneic transplantation (allo-HSCT) is still only an investigational procedure. Because of
high transplantation-related mortality myeloablative allografting is replaced by reduced-intensity
conditioning (RIC) after a debulky autologous transplantation.
Hematologia 2011; 2, 2: 131–139
Hematologia 2011; 2, 2: 131–139
Keywords: plasma cell myelomahematopoietic stem cell transplantationreduced intensity conditioningthalidomidelenalidomidebortezomib
